openPR Logo
Press release

Myositis Pipeline Outlook Report 2024 | Latest Drugs Approvals, FDA, Clinical Trials and Companies

06-18-2024 05:52 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Myositis Pipeline

Myositis Pipeline

DelveInsight's, "Myositis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myositis pipeline landscape. It covers the Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Myositis Pipeline Report
• DelveInsight's Myositis pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myositis treatment.
• The leading companies working in the Myositis Market include Pharmaceuticals, Janssen Research & Development, LLC, Pfizer, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Paean Biotechnology Inc., Alexion Pharmaceuticals, ImmunoForge, JN Biosciences, Merck KGaA, and others.
• Promising Myositis Pipeline Therapies in the various stages of development includes ABC008, Daxdilimab, BYM338 (Bimagrumab), BYM338, Arimoclomol, Nipocalimab, Glucocorticoids, and others.
• April 2024:- Abcuro Inc. - A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis. The study will include a sentinel cohort (Part A) of 30 subjects who will receive first three doses of the study drug. Safety data from subjects in the sentinel cohorts will be evaluated by a Data and Safety Monitoring Board (DSMB) before further dosing of the sentinel cohort, as well as initiation of enrollment in the double-blind safety and efficacy cohort (Part B).
• April 2024:- Pfizer announced a study of Phase 3 clinical trials for PF-06823859. The study will compare the experiences of people receiving study medication to those of the people who do not. This will help to see if PF-06823859 is safe and effective. Participants will take part in this study for about 13 months. During this time, participants will have 16 study visits. These visits will be performed at the study site.

Request a sample and discover the recent advances in Myositis Treatment Drugs @ Myositis Pipeline Report- https://www.delveinsight.com/report-store/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Myositis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Myositis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Myositis clinical trial landscape.

Myositis Overview
The term "myositis" refers to a general inflammation or swelling of the muscle. Many people have experienced sore muscles after vigorous exercise, a condition that is temporary and improves with rest.

Find out more about Myositis Treatment Landscape @ Drugs for Myositis Treatment- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Myositis Emerging Drugs Profile
• Lenabasum: Corbus Pharmaceuticals
• Nipocalimab: Janssen Research & Development, LLC

Myositis Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Myositis. The Myositis companies which have their Myositis drug candidates in the most advanced stage, i.e. phase III include, Corbus Pharmaceuticals.

Learn more about the emerging Myositis Pipeline Therapies @ Myositis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Myositis Pipeline Report
• Coverage- Global
• Allergic Conjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Allergic Conjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Myositis Companies- Corbus Pharmaceuticals, Janssen Research & Development, LLC, Pfizer, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Paean Biotechnology Inc., Alexion Pharmaceuticals, ImmunoForge, JN Biosciences, Merck KGaA, and others.
• Myositis Pipeline Therapies- ABC008, Daxdilimab, BYM338 (Bimagrumab), BYM338, Arimoclomol, Nipocalimab, Glucocorticoids, and others.

Dive deep into rich insights for new drugs for Myositis Treatment, Visit @ Myositis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Myositis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myositis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Lenabasum: Corbus Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Nipocalimab: Janssen Research & Development, LLC
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Myositis Key Companies
18. Myositis Key Products
19. Myositis- Unmet Needs
20. Myositis- Market Drivers and Barriers
21. Myositis- Future Perspectives and Conclusion
22. Myositis Analyst Views
23. Myositis Key Companies
24. Appendix

For further information on the Myositis Pipeline therapeutics, reach out to Myositis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
Uveitis Market- https://www.delveinsight.com/report-store/uveitis-market
Hidradenitis Suppurativa Market- https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market
Peripheral T-cell Lymphoma Market- https://www.delveinsight.com/report-store/peripheral-t-cell-lymphoma-ptcl-market
Glaucoma Market- https://www.delveinsight.com/report-store/glaucoma-market
Retinitis Pigmentosa Market- https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
Oropharyngeal Cancer Market- https://www.delveinsight.com/report-store/oropharyngeal-cancer-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Paranasal Sinus Cancer Market- https://www.delveinsight.com/report-store/paranasal-sinus-cancer-market
Castration-resistant Prostate Cancer Market- https://www.delveinsight.com/report-store/castration-resistant-prostate-cancer-crpc-market
Opioid Withdrawal Syndrome Market- https://www.delveinsight.com/report-store/opioid-withdrawal-syndrome-market
Complicated Urinary Tract Infections Market- https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market
Cervical Dystonia Market- https://www.delveinsight.com/report-store/cervical-dystonia-market
Schizophrenia Market- https://www.delveinsight.com/report-store/schizophrenia-market-insight
Focal Segmental Glomerulosclerosis Market- https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market
Obstructive Sleep Apnea Market- https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
Severe Hypertriglyceridemia Market- https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market
Short Bowel Syndrome Market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
Complement 3 Glomerulopathy Market- https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
Aplastic Anemia Market- https://www.delveinsight.com/report-store/aplastic-anemia-market
Nephrotic Syndrome Market- https://www.delveinsight.com/report-store/nephrotic-syndrome-market
Pulmonary Arterial Hypertension Market- https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
Hemophilia A Market- https://www.delveinsight.com/report-store/hemophilia-a2030-market
Complicated Urinary Tract Infections Market- https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Myositis Pipeline Outlook Report 2024 | Latest Drugs Approvals, FDA, Clinical Trials and Companies here

News-ID: 3542186 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Myositis

Inclusion Body Myositis Market: A Guide to Understanding the Process
The global Inclusion Body Myositis (IBM) market is projected to reach approximately USD 231.4 million by 2033, growing at a CAGR of 8.7% from 2024 to 2033. Inclusion Body Myositis Market Overview The Inclusion Body Myositis market is growing steadily due to increasing recognition and diagnosis of this rare neuromuscular disorder. Advances in therapeutic research focusing on inflammation and muscle degeneration are driving the development of targeted treatments. Rising patient awareness and
Myositis Clinical Trials, Pipeline Insights, and Companies 2024
DelveInsight's, "Myositis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myositis pipeline landscape. It covers the Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Request a sample and discover the recent advances in Myositis Treatment
Myositis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 202 …
DelveInsight's, "Myositis Pipeline Insight 2023," report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myositis pipeline landscape. It covers the Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Myositis Pipeline Report • DelveInsight's Myositis pipeline report
Global Necrotizing Autoimmune Myositis Market - Opportunities & Forecasts, 2020- …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global necrotizing autoimmune myositis market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future. Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Clinic …
Market Research HUB's latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2017, provides an overview of the Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline landscape. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1196670 Fibrodysplasia Ossificans Progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside that constrains movement.
Inclusion Body Myositis (IBM) - Pipeline Review And Industry Insight Report 2017
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and